Novel insights into the association between genetically proxied inhibition of proprotein convertase subtilisin/kexin type 9 and risk of sarcopenia

IF 8.9 1区医学

Journal of Cachexia, Sarcopenia and Muscle Pub Date : 2024-09-10 DOI:10.1002/jcsm.13575

Hongyan Jiang, Lulu Li, Xue Zhang, Jia He, Chuanhuai Chen, Ruimin Sun, Ying Chen, Lijuan Xia, Lei Wen, Yunxiang Chen, Junxiu Liu, Lijiang Zhang, Wanqiang Lv

引用次数: 0

Abstract

The effects of lipid-lowering drugs [including statins, ezetimibe, and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors] on hyperlipidaemia have been established. Some may have treatment effects beyond their reported properties, offering potential opportunities for drug repurposing. Epidemiological studies have reported conflicting findings on the relationship between lipid-lowering medication use and sarcopenia risk.

查看原文本刊更多论文

从基因角度看9型枯草蛋白酶/kexin抑制与肌肉疏松症风险之间关系的新见解

降脂药物[包括他汀类药物、依折麦布和9型(PCSK9)酶抑制剂]对高脂血症的影响已经确立。其中一些药物的治疗效果可能超出了其报告的特性，这为药物的再利用提供了潜在的机会。关于降脂药物的使用与肌肉疏松症风险之间的关系，流行病学研究报告的结果相互矛盾。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cachexia, Sarcopenia and Muscle Medicine-Orthopedics and Sports Medicine

自引率

12.40%

发文量

期刊介绍： The Journal of Cachexia, Sarcopenia, and Muscle is a prestigious, peer-reviewed international publication committed to disseminating research and clinical insights pertaining to cachexia, sarcopenia, body composition, and the physiological and pathophysiological alterations occurring throughout the lifespan and in various illnesses across the spectrum of life sciences. This journal serves as a valuable resource for physicians, biochemists, biologists, dieticians, pharmacologists, and students alike.